Pharma major Venus Remedies has received marketing authorisations for three variants of Docetaxel in Israel and Cytarabjne 100MG in Colombia.
According to the company’s regulatory filing, the approved Docetaxel variants are 160MG/8ML, 80MG/4ML, 20MG/1ML.
The Venus Remedies stock surged by 7.15 per cent on the NSE, at ₹403.30, as of 1:31 pm on Thursday.
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.